Screener
Alto Neuroscience ANRO Other operating expenses
Other operating expenses at other companies
Other financials
Where this comes from
Reported directly by Alto Neuroscience in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: Alto Neuroscience’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 7:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001999480-26-000012
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | $20,294 | $9,974 |
| General and administrative | 6,844 | 5,702 |
| Total operating expenses | 27,138 | 15,676 |
| Loss from operations | (27,138) | (15,676) |
| Other income (expense): | ||
| Interest income | 1,561 | 1,827 |
| Interest expense | (545) | (598) |
Item 1. Financial Statements (Unaudited).
FAQ
- What is Alto Neuroscience's other operating expenses?
- Alto Neuroscience (ANRO) reported other operating expenses of $27.14M in Q1 2026.
- How has Alto Neuroscience's other operating expenses changed year-over-year?
- Alto Neuroscience's other operating expenses increased by 73.1% year-over-year, from $15.68M to $27.14M.
- What is the long-term trend for Alto Neuroscience's other operating expenses?
- Over 2 years (2023 to 2025), Alto Neuroscience's other operating expenses has grown at a 32.5% compound annual growth rate (CAGR), from $37.81M to $66.36M.
- What does other operating expenses mean?
- Residual operating expenses not classified into specific categories, serving as a catch-all for miscellaneous operating costs.
Ask your AI about Alto Neuroscience's other operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude